Provided by Tiger Trade Technology Pte. Ltd.

Repligen

110.12
-4.3000-3.76%
Post-market: 110.120.00000.00%19:23 EDT
Volume:826.92K
Turnover:91.88M
Market Cap:6.20B
PE:128.05
High:114.41
Open:113.31
Low:109.66
Close:114.42
52wk High:175.77
52wk Low:102.97
Shares:56.29M
Float Shares:52.66M
Volume Ratio:0.95
T/O Rate:1.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.8600
EPS(LYR):0.8600
ROE:2.40%
ROA:0.99%
PB:2.94
PE(LYR):128.05

Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Repligen (RGEN), Myriad Genetics (MYGN)

TIPRANKS
·
Feb 24

Stock Track | Repligen Plunges 5.48% in Pre-market on Weak FY26 Earnings Guidance

Stock Track
·
Feb 24

GUIDANCE: (RGEN) Repligen Expects Full Year 2026 Revenue Range $810M - $840M, vs. FactSet Est of $822.5M

MT Newswires Live
·
Feb 24

Repligen Q4 Adj. EPS $0.49 Beats $0.44 Estimate, Sales $197.913M Beat $192.907M Estimate

Benzinga
·
Feb 24

Repligen Q4 revenue beats estimates on Analytics and Proteins growth

Reuters
·
Feb 24

Repligen reports Q4 adjusted EPS 49c, consensus 44c

TIPRANKS
·
Feb 24

Repligen sees FY26 EPS $1.93-$2.01, consensus $2.07

TIPRANKS
·
Feb 24

Repligen Q4 revenue rises 18% to USD 198 million

Reuters
·
Feb 24

BRIEF-Repligen Q4 Adjusted EPS USD 0.49 Vs. IBES Estimate USD 0.44

Reuters
·
Feb 24

Corrected-Repligen Outlook FY Adj EPS USD 1.93-2.01 (Adds Dropped Word 'Adj')

THOMSON REUTERS
·
Feb 24

Repligen Outlook FY EPS USD 1.93-2.01

THOMSON REUTERS
·
Feb 24

Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

THOMSON REUTERS
·
Feb 24

Earning Preview: Repligen Q4 revenue is expected to increase by 15.05%, and institutional views are cautiously positive

Earnings Agent
·
Feb 17

Repligen Corporation to Announce Fourth Quarter and Full Year Financial Results

Reuters
·
Feb 10

Q/C Technologies Inc. Files Initial Beneficial Ownership Statement for Director Chelsea Sierra Voss

Reuters
·
Jan 31

Q/C Technologies Appoints AI Expert Chelsea Voss to Board

Reuters
·
Jan 26

Q/C Technologies Appoints Chelsea Voss to Board of Directors

Reuters
·
Jan 20

Repligen Is Maintained at Buy by UBS

Dow Jones
·
Jan 17

UBS Adjusts Price Target on Repligen to $200 From $190, Maintains Buy Rating

MT Newswires Live
·
Jan 16

Repligen Corporation Files Initial Statement of Beneficial Ownership for Chief Product Officer Brian Robb

Reuters
·
Jan 13